Collectively these results suggest that in serine synthesis-deficient tumors, targeting SLC6A14 together with an ion exchanger/facilitator (SLC12A4) or a mitochondrial serine transporter (SLC25A15) can decrease serine uptake, leading to reduced tumor growth. The gene discussed is SLC25A15; the disease is neoplasm.